These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 32699136)

  • 1. P2X7 Receptor Activity Limits Accumulation of T Cells within Tumors.
    Romagnani A; Rottoli E; Mazza EMC; Rezzonico-Jost T; De Ponte Conti B; Proietti M; Perotti M; Civanelli E; Perruzza L; Catapano AL; Baragetti A; Tenedini E; Tagliafico E; Falzoni S; Di Virgilio F; Norata GD; Bicciato S; Grassi F
    Cancer Res; 2020 Sep; 80(18):3906-3919. PubMed ID: 32699136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The P2X7 receptor modulates immune cells infiltration, ectonucleotidases expression and extracellular ATP levels in the tumor microenvironment.
    De Marchi E; Orioli E; Pegoraro A; Sangaletti S; Portararo P; Curti A; Colombo MP; Di Virgilio F; Adinolfi E
    Oncogene; 2019 May; 38(19):3636-3650. PubMed ID: 30655604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P2RX7 Enhances Tumor Control by CD8+ T Cells in Adoptive Cell Therapy.
    Wanhainen KM; Peng C; Zhou MH; Macedo BG; O'Flanagan S; Yang T; Kelekar A; Burbach BJ; Borges da Silva H; Jameson SC
    Cancer Immunol Res; 2022 Jul; 10(7):871-884. PubMed ID: 35588154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
    Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
    Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sialic Acid Blockade Suppresses Tumor Growth by Enhancing T-cell-Mediated Tumor Immunity.
    Büll C; Boltje TJ; Balneger N; Weischer SM; Wassink M; van Gemst JJ; Bloemendal VR; Boon L; van der Vlag J; Heise T; den Brok MH; Adema GJ
    Cancer Res; 2018 Jul; 78(13):3574-3588. PubMed ID: 29703719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility study of B16 melanoma therapy using oxidized ATP to target purinergic receptor P2X7.
    Hattori F; Ohshima Y; Seki S; Tsukimoto M; Sato M; Takenouchi T; Suzuki A; Takai E; Kitani H; Harada H; Kojima S
    Eur J Pharmacol; 2012 Nov; 695(1-3):20-6. PubMed ID: 22981895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD39 limits P2X7 receptor inflammatory signaling and attenuates sepsis-induced liver injury.
    Savio LEB; de Andrade Mello P; Figliuolo VR; de Avelar Almeida TF; Santana PT; Oliveira SDS; Silva CLM; Feldbrügge L; Csizmadia E; Minshall RD; Longhi MS; Wu Y; Robson SC; Coutinho-Silva R
    J Hepatol; 2017 Oct; 67(4):716-726. PubMed ID: 28554875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD8
    Mellouk A; Bobé P
    FASEB J; 2019 Mar; 33(3):3225-3236. PubMed ID: 30383448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiofrequency radiation reshapes tumor immune microenvironment into antitumor phenotype in pulmonary metastatic melanoma by inducing active transformation of tumor-infiltrating CD8
    Jiao JZ; Zhang Y; Zhang WJ; He MD; Meng M; Liu T; Ma QL; Xu Y; Gao P; Chen CH; Zhang L; Pi HF; Deng P; Wu YZ; Zhou Z; Yu ZP; Deng YC; Lu YH
    Acta Pharmacol Sin; 2024 Jul; 45(7):1492-1505. PubMed ID: 38538718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting
    Le PT; Ha N; Tran NK; Newman AG; Esselen KM; Dalrymple JL; Schmelz EM; Bhandoola A; Xue HH; Singh PB; Thai TH
    Front Immunol; 2021; 12():738958. PubMed ID: 34721405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine triphosphate.
    Feng L; Sun X; Csizmadia E; Han L; Bian S; Murakami T; Wang X; Robson SC; Wu Y
    Neoplasia; 2011 Mar; 13(3):206-16. PubMed ID: 21390184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitochondrial arginase-2 is a cell‑autonomous regulator of CD8+ T cell function and antitumor efficacy.
    Martí i Líndez AA; Dunand-Sauthier I; Conti M; Gobet F; Núñez N; Hannich JT; Riezman H; Geiger R; Piersigilli A; Hahn K; Lemeille S; Becher B; De Smedt T; Hugues S; Reith W
    JCI Insight; 2019 Nov; 4(24):. PubMed ID: 31751318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ATP-P2X7-Induced Inflammasome Activation Contributes to Melanocyte Death and CD8
    Ahn Y; Seo J; Lee EJ; Kim JY; Park MY; Hwang S; Almurayshid A; Lim BJ; Yu JW; Oh SH
    J Invest Dermatol; 2020 Sep; 140(9):1794-1804.e4. PubMed ID: 32035094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abscopal Effects With Hypofractionated Schedules Extending Into the Effector Phase of the Tumor-Specific T-Cell Response.
    Zhang X; Niedermann G
    Int J Radiat Oncol Biol Phys; 2018 May; 101(1):63-73. PubMed ID: 29534901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
    Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
    Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The purinergic receptor P2RX7 directs metabolic fitness of long-lived memory CD8
    Borges da Silva H; Beura LK; Wang H; Hanse EA; Gore R; Scott MC; Walsh DA; Block KE; Fonseca R; Yan Y; Hippen KL; Blazar BR; Masopust D; Kelekar A; Vulchanova L; Hogquist KA; Jameson SC
    Nature; 2018 Jul; 559(7713):264-268. PubMed ID: 29973721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving function of cytotoxic T-lymphocytes by transforming growth factor-β inhibitor in oral squamous cell carcinoma.
    Kondo Y; Suzuki S; Takahara T; Ono S; Goto M; Miyabe S; Sugita Y; Ogawa T; Ito H; Satou A; Tsuzuki T; Yoshikawa K; Ueda R; Nagao T
    Cancer Sci; 2021 Oct; 112(10):4037-4049. PubMed ID: 34309966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inactivation of Proprotein Convertases in T Cells Inhibits PD-1 Expression and Creates a Favorable Immune Microenvironment in Colorectal Cancer.
    Tomé M; Pappalardo A; Soulet F; López JJ; Olaizola J; Leger Y; Dubreuil M; Mouchard A; Fessart D; Delom F; Pitard V; Bechade D; Fonck M; Rosado JA; Ghiringhelli F; Déchanet-Merville J; Soubeyran I; Siegfried G; Evrard S; Khatib AM
    Cancer Res; 2019 Oct; 79(19):5008-5021. PubMed ID: 31358531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of SHP-1 Expands the Repertoire of Antitumor T Cells Available to Respond to Immune Checkpoint Blockade.
    Snook JP; Soedel AJ; Ekiz HA; O'Connell RM; Williams MA
    Cancer Immunol Res; 2020 Apr; 8(4):506-517. PubMed ID: 32075800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.